Australia Approves First GLP-1 Weight-Loss Pill
Australia Approves First GLP-1 Weight-Loss Pill
Australia Approves First GLP-1 Weight-Loss Pill
Key points
اہم نکات
मुख्य बातें
- Australia has approved its first GLP-1 weight-loss pill, a daily tablet version of Wegovy, the Australian Women's Weekly reports.
- The Therapeutic Goods Administration approved the drug on 3 November, making it the first oral GLP-1 medicine cleared in Australia specifically for weight management.
- The tablet contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic, and comes in four strengths: 1.5mg, 4mg, 9mg and 25mg.
- Australia has approved its first GLP-1 weight-loss pill, a daily tablet version of Wegovy, the Australian Women's Weekly reports.
- The Therapeutic Goods Administration approved the drug on 3 November, making it the first oral GLP-1 medicine cleared in Australia specifically for weight management.
- The tablet contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic, and comes in four strengths: 1.5mg, 4mg, 9mg and 25mg.
- Australia has approved its first GLP-1 weight-loss pill, a daily tablet version of Wegovy, the Australian Women's Weekly reports.
- The Therapeutic Goods Administration approved the drug on 3 November, making it the first oral GLP-1 medicine cleared in Australia specifically for weight management.
- The tablet contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic, and comes in four strengths: 1.5mg, 4mg, 9mg and 25mg.
Australia has approved its first GLP-1 weight-loss pill, a daily tablet version of Wegovy, the Australian Women's Weekly reports. The Therapeutic Goods Administration approved the drug on 3 November, making it the first oral GLP-1 medicine cleared in Australia specifically for weight management. The tablet contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic, and comes in four strengths: 1.5mg, 4mg, 9mg and 25mg. It is for adults with a body mass index of 30 or more, or 27 or more with a weight-related health condition, alongside a reduced-energy diet and more exercise. It offers an alternative to weekly injections, but it is not in pharmacies yet: final packaging checks are still to come, Novo Nordisk aims to have it available by the end of 2026, and there is no confirmed price or PBS subsidy for weight loss.
Australia has approved its first GLP-1 weight-loss pill, a daily tablet version of Wegovy, the Australian Women's Weekly reports. The Therapeutic Goods Administration approved the drug on 3 November, making it the first oral GLP-1 medicine cleared in Australia specifically for weight management. The tablet contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic, and comes in four strengths: 1.5mg, 4mg, 9mg and 25mg. It is for adults with a body mass index of 30 or more, or 27 or more with a weight-related health condition, alongside a reduced-energy diet and more exercise. It offers an alternative to weekly injections, but it is not in pharmacies yet: final packaging checks are still to come, Novo Nordisk aims to have it available by the end of 2026, and there is no confirmed price or PBS subsidy for weight loss.
Australia has approved its first GLP-1 weight-loss pill, a daily tablet version of Wegovy, the Australian Women's Weekly reports. The Therapeutic Goods Administration approved the drug on 3 November, making it the first oral GLP-1 medicine cleared in Australia specifically for weight management. The tablet contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic, and comes in four strengths: 1.5mg, 4mg, 9mg and 25mg. It is for adults with a body mass index of 30 or more, or 27 or more with a weight-related health condition, alongside a reduced-energy diet and more exercise. It offers an alternative to weekly injections, but it is not in pharmacies yet: final packaging checks are still to come, Novo Nordisk aims to have it available by the end of 2026, and there is no confirmed price or PBS subsidy for weight loss.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।